Welcome to our dedicated page for Trinity Biotech Plc SEC filings (Ticker: TRIB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Trinity Biotech plc (TRIB) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including Form 20-F annual reports and Form 6-K current reports. As a foreign private issuer listed on the Nasdaq Stock Market, Trinity Biotech uses these filings to furnish information on its human diagnostics and diabetes management business, financing arrangements and governance matters.
Form 6-K reports for TRIB frequently include press releases as exhibits, covering topics such as regulatory approvals for offshored and outsourced manufacturing of its TrinScreen HIV and Uni-Gold HIV rapid tests, expansion of its high-capacity HbA1c column system for the Premier Hb9210 analyzer, collaboration on epigenetic analysis for the EpiCapture prostate cancer test, and regulatory clearance for the PreClara Ratio preeclampsia testing service. Other 6-K filings reference amendments to credit agreements with Perceptive Credit Holdings entities, warrant issuances, and results of annual general meetings, including resolutions on auditor appointment and share capital authorities.
Users interested in Trinity Biotech’s capital structure and risk profile can review filings that discuss its term-loan facility, amendments and restatements of its credit agreement, and arrangements that allow potential conversion of portions of debt and certain obligations into equity. Filings also document interactions with Nasdaq regarding listing requirements, such as notices of non-compliance with minimum bid price and market value of publicly held shares thresholds, and subsequent confirmation that the company has regained compliance.
Stock Titan enhances access to these documents with tools that surface key elements of each filing, helping readers quickly identify material related to product approvals, financing terms, shareholder votes and other regulatory disclosures. This allows investors, analysts and other stakeholders to examine the official record of Trinity Biotech’s activities as reported to the U.S. Securities and Exchange Commission.
TRINITY BIOTECH PLC filed a Form 3 to report that Paul Murphy, the company’s Interim CFO, is now an insider required to report holdings and future trades in the company’s securities. The filing lists no initial share or option positions and shows no buy, sell, or exercise activity.
Trinity Biotech plc director John Paul Tivnan has filed a Form 3 insider ownership report for ticker TRIB. The data provided show no reported transactions, with buy, sell, exercise, gift, tax withholding, and restructuring share counts all at zero, indicating purely a baseline regulatory filing.
TRINITY BIOTECH PLC director John Gillard filed an initial statement of beneficial ownership, showing holdings of ADS options and common ADS. The filing lists multiple option grants over TRIB ADS with exercise prices between $2.40 and $13.45, plus 10,000 ADS held directly.
Trinity Biotech plc director Andrew Omidvar filed an initial Form 3 reporting holdings of ADS options. The options have an exercise price of $2.80 per ADS and expire on February 2, 2031. Multiple option tranches cover underlying ADS amounts of 7,292 and 2,917, with various future exercise dates extending into 2027.
Trinity Biotech plc announced successful clinical study results for an enhanced version of its EpiCapture™ prostate cancer test and outlined commercialization plans, while also obtaining a limited waiver under its Credit Agreement. The upgraded urine-based test now uses a machine learning algorithm that integrates DNA biomarkers with patient features such as ethnicity to improve individualized risk prediction for aggressive prostate cancer.
In an independently conducted study of approximately 750 patient samples, the next-generation EpiCapture™ achieved a clinical accuracy (AUC) of 85%, a level described as strong and clinically useful in oncology diagnostics. Trinity Biotech plans to launch EpiCapture™ in the U.S. as a proprietary Laboratory Developed Test through its New York reference laboratory, marking its first entry into precision oncology diagnostics. The company also disclosed that, under the limited waiver for covenant 8.15 with Perceptive Credit Holdings III, interest accruing in March 2026 will be capitalized and added to the principal balance of its debt.
Trinity Biotech plc filed a Form 6-K highlighting two growth initiatives in diabetes care. Senior executives are attending the ATTD 2026 conference in Barcelona to advance collaborations and commercialization plans for the next‑generation CGM+ continuous glucose monitoring platform, which is being prepared for a pivotal clinical trial in 2026.
The company has also begun commercial rollout in Brazil of its upgraded Premier Hb9210 HbA1c column system after local regulatory approval. The Premier Hb9210 platform is described as the only HbA1c system worldwide with IFCC “Gold” classification for 2026, and Trinity Biotech has strengthened its Brazilian commercial leadership with the appointment of Bruna Gigliotti.
Trinity Biotech plc is updating its Form F-1 prospectus to cover the resale by selling shareholders of up to 1,117,818,000 Ordinary Shares, represented by up to 55,890,900 ADSs. The ADSs trade on Nasdaq under the symbol TRIB and the last reported sale price on March 9, 2026 was $0.7010.
The supplement incorporates Form 6‑K materials filed March 10, 2026, including a press release describing technical breakthroughs for the company’s next‑generation CGM+ continuous glucose monitoring platform and a trading/business update that discloses a limited waiver and a covenant deferral under its Credit Agreement through July 1, 2026, and operational actions such as outsourcing Uni‑Gold™ HIV manufacturing.
Trinity Biotech plc updates its prospectus to register for resale up to 705,659,320 Ordinary Shares, represented by up to 35,282,966 ADSs. The supplement incorporates Form 6-K reports filed March 10, 2026, describing technical breakthroughs for its next‑generation CGM+ continuous glucose monitoring platform and a trading and business update.
The company reports substantial multi‑day clinical-data improvements in glucose measurement accuracy (material reduction in MARD), anticipates initiating a pivotal clinical trial in 2026, and states the CGM+ design targets modularity, multimodal sensing, and AI-native analytics. Separately, Trinity obtained a limited waiver and a covenant deferral under its credit agreement through July 1, 2026.
Trinity Biotech plc reports major technical progress on its next-generation, calibration‑free CGM+ continuous glucose monitoring platform, supported by more than 650 days of clinical testing data. The updated sensor and electronics architecture materially improved glucose measurement accuracy across multi‑day wear, indicating the system can meet modern CGM accuracy standards.
The company also developed a needle‑free insertion process and a modular device design aimed at lowering costs and improving sustainability versus current market‑leading CGMs. CGM+ uses multimodal sensing and AI‑native analytics to generate personalized metabolic health insights, and Trinity Biotech anticipates initiating a pivotal clinical trial in 2026, targeting regulatory submissions in key global markets afterward.
Trinity Biotech plc filed a Form 6-K sharing a trading and business update and disclosing amendments to its credit covenants. The company obtained a limited waiver of covenant 8.16 and a deferral of a scheduled change to covenant 8.15 under its Credit Agreement with Perceptive Credit Holdings III, both effective through July 1, 2026.
Operationally, Trinity Biotech is advancing a Comprehensive Transformation Plan aimed at improving long-term profitability. It received local regulatory approval in February 2026 to outsource and offshore production of its Uni-Gold HIV rapid test, enabling the final transition of manufacturing. Strong demand for Uni-Gold HIV and growing traction for TrinScreen are expected to increase the share of rapid HIV products in 2026 revenue, but order patterns and the outsourcing transition are anticipated to increase quarter‑on‑quarter revenue variability and shift some HIV revenue from Quarter 1 into Quarter 2 and from Quarter 2 into Quarter 3.
In diabetes care, the Premier Hb9210 HbA1c laboratory solution earned IFCC Gold Classification for 2026 and obtained multiple regulatory clearances for a next‑generation high‑capacity HbA1c column system. Trinity Biotech is intensifying commercial efforts in the United States, Brazil, and distributor markets, while also consolidating certain haemoglobin manufacturing processes at other group sites to expand capacity and reduce costs.